Personal tools

Sponsorname

Your company could advertise here

www.fla-consulting.eu

Reference:USA FDA Guidance for Industry - Oversight of Clinical Investigations β€” A Risk-Based Approach to Monitoring Aug-2013 III - IV.: Difference between revisions

From GxPlex

Jump to: navigation, search
gxplex>GxPlexBot
Import from GxPlex Excel
Migrate to Template:ReferenceData for PageForms (GxPlexBot)
Line 1: Line 1:
{{#set:
{{ReferenceData
|HasDocument=Document:USA FDA Guidance for Industry - Oversight of Clinical Investigations β€” A Risk-Based Approach to Monitoring Aug-2013
|has_document=Document:USA FDA Guidance for Industry - Oversight of Clinical Investigations β€” A Risk-Based Approach to Monitoring Aug-2013
|RefScope=G
|module=4
|RefDocPart=III - IV.
|unit=4.3.3
|RefLanguage=EN
|scope=G
|RefTags=TAG-00137-Mon-che ++ TAG-00293-Cen-sMo ++ TAG-00065-Sou-nΓΌb ++ TAG-00338-Met-odi ++ TAG-00327-Exa-spi
|doc_part=III - IV.
|RefModule=4
|language=EN
|RefUnit=4.3.3
|entry_by=Florian Adragna
}}
|contributors=
Β 
|tags=TAG-00137-Mon-che ++ TAG-00293-Cen-sMo ++ TAG-00065-Sou-nΓΌb ++ TAG-00338-Met-odi ++ TAG-00327-Exa-spi
{{:Document:USA FDA Guidance for Industry - Oversight of Clinical Investigations β€” A Risk-Based Approach to Monitoring Aug-2013}}
|tags_display=[[Glossary:TAG-00137-Mon-che|Monitoring]], [[Glossary:TAG-00293-Cen-sMo|Centralised monitoring]], [[Glossary:TAG-00065-Sou-nΓΌb|Source data verification]], [[Glossary:TAG-00338-Met-odi|Methodology]], [[Glossary:TAG-00327-Exa-spi|Examples]]
Β 
|comment=Overview of on-site and centralised monitoring methods
{| class="wikitable gplx-infobox"
|content=III. OVERVIEW OF MONITORING METHODS
|-
! colspan="2" class="gplx-infobox-header" | Reference Details
|-
! Module
| Module 4 β€” Unit 4.3.3
|-
! Scope
| G
|-
! Document part
| III - IV.
|-
! Language
| EN
|-
! Original entry by
| Florian Adragna
|-
! Contributors
|
|-
! Tags
| [[Glossary:TAG-00137-Mon-che|Monitoring]], [[Glossary:TAG-00293-Cen-sMo|Centralised monitoring]], [[Glossary:TAG-00065-Sou-nΓΌb|Source data verification]], [[Glossary:TAG-00338-Met-odi|Methodology]], [[Glossary:TAG-00327-Exa-spi|Examples]]
|-
! Comment
| Overview of on-site and centralised monitoring methods
|}
Β 
== Content ==
III. OVERVIEW OF MONITORING METHODS
A. On-Site and Centralized Monitoring
A. On-Site and Centralized Monitoring
1. On-Site Monitoring
1. On-Site Monitoring
Line 59: Line 29:
4. Ensuring Quality Monitoring
4. Ensuring Quality Monitoring
5. Monitoring Plan Amendments
5. Monitoring Plan Amendments
}}

Revision as of 12:56, 16 July 2026



Document information
Reference USA FDA Guidance for Industry -

Oversight of Clinical Investigations β€” A Risk-Based Approach to Monitoring Aug-2013

Validity area USA
Scope(s) G
Document name FDA Guidance for Industry -

Oversight of Clinical Investigations β€” A Risk-Based Approach to Monitoring

Version / Revision Aug-2013
Status Current
Document type Official recommendation
Language(s) EN
Description Oversight of Clinical Investigations β€” A Risk-Based Approach to Monitoring

Guidance for Industry

Official source Official link
Restricted access No
Submitted by Florian Adragna
Contributors


Reference Details
Module Module 4 β€” Unit 4.3.3
Scope G
Document part III - IV.
Language EN
Original entry by Florian Adragna
Contributors
Tags Monitoring, Centralised monitoring, Source data verification, Methodology, Examples

Content

III. OVERVIEW OF MONITORING METHODS A. On-Site and Centralized Monitoring 1. On-Site Monitoring 2. Centralized Monitoring B. Examples of Alternative Monitoring Techniques 1. Communication with Study Site Staff2. Review of Site’s Processes, Procedures, and Records 3. Source Data Verification and Corroboration

IV. RISK-BASED MONITORING A. Identify Critical Data and Processes to be Monitored B. Risk Assessment C. Factors to Consider when Developing a Monitoring Plan D. Monitoring Plan 1. Description of Monitoring Approaches 2. Communication of Monitoring Results 3. Management of Noncompliance 4. Ensuring Quality Monitoring 5. Monitoring Plan Amendments